A Phase 3 interventional study of Teduglutide and SOC in Short Bowel Syndrome, sponsored by Shire. Completed at 11 sites in 2 countries. Per ClinicalTrials.gov, last updated 2025-03-19.
Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing teduglutide in Short Bowel Syndrome — 1 open to participants now, 2 under way, 1 of them phase 3. teduglutide · Short Bowel Syndrome.
Among the 20 studies testing teduglutide in Short Bowel Syndrome, this one is the 9th largest by enrollment, is one of 2 that started in 2016, is one of 16 in phase 3, and was the 11th registered.
159 studies on the registry are indexed under Short Bowel Syndrome; 24 are open to participants now.
Browse Short Bowel Syndrome studies →1 of the 20 studies testing teduglutide in Short Bowel Syndrome is open now, in 1 country. Recruiting first, the newest first:
Meyer Children's Hospital IRCCS · Sites in Italy
Ages 4 mo–17 yrs
By country, each count listing its studies:
teduglutide: first FDA approval 2012 (GATTEX KIT), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 18 Short Bowel Syndrome studies recruiting now, 8 (44%) set no upper age limit and 8 (44%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2016.
This study's enrollment of 29 is above the median of 21 across 108 interventional studies indexed under Short Bowel Syndrome.
Median enrollment 20 across the 20 interventional studies. Of the 18 that completed or were terminated, 16 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 20 have an industry lead sponsor. The 6 most frequent:
This study is registered under Shire, one of the names counted as Takeda. Under that name alone:
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
26 studies in Short Bowel Syndrome by Takeda: 1 open now, 3 under way, 1 of them phase 3. Of 23 finished, 16 (70%) have results posted.
Among the 26 studies in Short Bowel Syndrome by Takeda, this one is the 9th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2016, is one of 17 in phase 3, and was the 11th registered.
Takeda’s Short Bowel Syndrome studies by the year they started, since 2004.
1 of the studies testing teduglutide in Short Bowel Syndrome that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06973304Phase 3TakedaA Study of Teduglutide in Chinese Adults With Short Bowel Syndrome | 2027-02-10 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies testing teduglutide in Short Bowel Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 26 in Short Bowel Syndrome:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and efficacy of teduglutide treatment of children with short bowel syndrome (SBS) who completed the TED-C13-003 study over a long-term period. It will evaluate how these children fared after the TED-C13-003 study ended. This study will also offer teduglutide treatment to eligible subjects, regardless of treatment received in TED-C13-003.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
There are no exclusion criteria for this study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TED 0.05mg/kg subcutaneous injections once daily as needed in addition to SOC treatment
Drug: Teduglutide · Other: SOC
0.05mg/kg
Standard safety assessments and adjustments in nutritional support will be provided for all subjects throughout the study, including any teduglutide treatment periods
Number of Participants With Adverse Events (AEs) in Retrospective Observation Period
An AE was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. A SAE was any untoward medical occurrence (whether considered to be related to investigational product or not) that at any dose: results in death, was life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, was a congenital abnormality/birth defect, was an important medical event. Number of participants with AEs, related AEs, serious adverse events (SAEs) and related SAEs of retrospective observation period were reported.
Time frame: From end of the core study (TED-C13-003 [NCT01952080]) up to the beginning of the prospective period (up to Week 168)
Change From Baseline in Height for Age Z-score up to Week 168 of Retrospective Observation Period
Height was measured using age Z-score. Z-score was calculated as (observed value - median value of the reference population) / standard deviation value of reference population. Centers for Disease Control and Prevention (age greater than or equal to \[\>=\] 2 years old) and World Health Organization (age less than \[\<\] 2 years old) Z-score calculation charts are used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in height for age Z-score up to Week 168 of retrospective observation period was reported. Data for this outcome was not planned to be collected and analyzed in retrospective TED/TED group.
Time frame: Baseline (Baseline visit in the core study [TED-C13-003 (NCT01952080)]) up to the beginning of the prospective period (up to Week 168)
Change From Baseline in Body Weight for Age Z-score up to Week 168 of Retrospective Observation Period
Body weight was measured using age Z-score. Z-score was calculated as (observed value - median value of the reference population) / standard deviation value of reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts are used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in body weight for age Z-score up to Week 168 was reported. Data for this outcome was not planned to be collected and analyzed in retrospective TED/TED group.
Time frame: Baseline (Baseline visit in the core study [TED-C13-003 (NCT01952080)]) up to the beginning of the prospective period (up to Week 168)
Change From Baseline in Body Mass Index (BMI) for Age Z-score up to Week 168 of Retrospective Observation Period
BMI Z-score was calculated by using the retrospective height and weight data. Z-score was calculated as (observed value - median value of the reference population) / standard deviation value of reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts are used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in height for age Z-score up to Week 168 of retrospective observation period was reported. Data for this outcome was not planned to be collected and analyzed in retrospective TED/TED group.
Time frame: Baseline (Baseline visit in the core study [TED-C13-003 (NCT01952080)]) up to the beginning of the prospective period (up to Week 168)
Number of Participants With Treatment Emergent Adverse Events (TEAEs) of Prospective Study Period
TEAEs are defined as AEs that started or worsened on or after the first dose of teduglutide treatment in the core study. A SAE was any untoward medical occurrence (whether considered to be related to investigational product or not) that at any dose: results in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, was a congenital abnormality/birth defect, was an important medical event. AESI was an TEAE or TESAE of scientific and medical concern specific to the sponsor's product or program and for which ongoing monitoring and immediate notification by the investigator to the sponsor. Number of participants With TEAEs, treatment -emergent serious adverse events (TESAEs) and adverse events of special interest (AESI) of Prospective study period were reported.
Time frame: From the beginning of the prospective study period to End of Study (EOS) (up to Week 144)
Change From Baseline in Height for Age Z-score up to Cycle 6 Week 12 During the End of Teduglutide Treatment Period of Prospective Study Period
Height was measured using age Z-score. Z-score was calculated as (observed value - median value of the reference population) / standard deviation value of reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts are used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in height for age Z-score up to Cycle 6 Week 12 during the end of teduglutide treatment period in prospective study period was reported.
Time frame: Baseline (from the beginning of the prospective study period) up to Cycle 6 Week 12
Change From Baseline in Body Weight for Age Z-score up to Cycle 6 Week 24 During the End of Teduglutide Treatment Period of Prospective Study Period
Body weight was measured using age Z-score. Z-score was calculated as (observed value - median value of the reference population) / standard deviation value of reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts are used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in body weight for age Z-score up to Cycle 6 Week 24 during the end of teduglutide treatment period of prospective study period was reported.
Time frame: Baseline (from the beginning of the prospective study period) up to Cycle 6 Week 24
Change From Baseline in BMI for Age Z-score up to Cycle 6 Week 12 During the End of Teduglutide Treatment Period of Prospective Study Period
BMI Z-score was calculated by using the height and weight data. Z-score was calculated as (observed value - median value of the reference population) / standard deviation value of reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts are used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in BMI for age Z-score up to Cycle 6 Week 12 during the end of teduglutide treatment period of prospective study period was reported.
Time frame: Baseline (from the beginning of the prospective study period) up to Cycle 6 Week 12
Average Total 48-Hour Urine Output up to Cycle 6 Week 12 During the End of Teduglutide Treatment Period of Prospective Study Period
Average total urine output was calculated based on the daily data recorded in participants diaries over a 48-hour period of nutritional stability prior to each scheduled visit. Average total 48-Hour urine output up to Cycle 6 Week 12 during the end of teduglutide treatment period of prospective study period was reported. Here, mL/kg/day is abbreviated as milliliter per kilogram per day.
Time frame: Baseline (from the beginning of the prospective study period) up to Cycle 6 Week 12
Average Total 48-Hour Urine Output up to Week 108 During the End of Non-Teduglutide Treatment (NTT) Period of Prospective Study Period
Average total urine output was calculated based on the daily data recorded in participants diaries over a 48-hour period of nutritional stability prior to each scheduled visit. Average total 48-Hour urine output up to Week 108 during the end of NTT period in prospective study period was reported.
Time frame: Baseline (from the beginning of the prospective study period) up to Week 108
Average Number of Stools Per Day up to Cycle 6 Week 24 During the End of Teduglutide Treatment Period of Prospective Study Period
Average number of stools per day was calculated based on the daily data recorded in participants diaries over a 48-hour period of nutritional stability prior to each scheduled visit. Average number of stools per day up to cycle 6 week 24 during the end of teduglutide treatment period in prospective study period was reported.
Time frame: Baseline (from the beginning of the prospective study period) up to Cycle 6 Week 24
Average Number of Stools Per Day up to Week 120 During the End of NTT Period of Prospective Study Period
Average number of stools per day was calculated based on the daily data recorded in participants diaries over a 48-hour period of nutritional stability prior to each scheduled visit. Average number of stools per day up to Week 120 during the end of NTT period in prospective study period was reported.
Time frame: Baseline (from the beginning of the prospective study period) up to Week 120
Number of Participants With Positive Specific Antibodies at EOS During the End of Teduglutide Treatment Period of Prospective Study Period
Number of participants with positive specific antibodies to teduglutide were used to summarize the presence of antibodies.
Time frame: From the beginning of the prospective study period, EOS (up to Week 156)
Number of Participants Achieved At Least 20 Percent (%) Reduction in Parenteral Support (PS) Volume at 12 Weeks Interval up to Week 156 of Retrospective Observation Period
Number of participants achieved at least 20% reduction in PS volume at 12 weeks interval up to Week 156 in retrospective observation period was reported.
Time frame: At Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, and 156
Change From Baseline in PS Volume at 12 Weeks Interval up to Week 156 of Retrospective Observation Period
Change from baseline in PS volume at 12 weeks interval up to Week 156 in retrospective observation period was reported.
Time frame: Baseline (Baseline visit in the core study [TED-C13-003 (NCT01952080)]), Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, and 156
Percent Change From Baseline in PS Volume at 12 Weeks Interval up to Week 156 of Retrospective Observation Period
Percent change from baseline in PS volume at 12 weeks interval up to Week 156 of retrospective observation period was reported.
Time frame: Baseline (Baseline visit in the core study [TED-C13-003 (NCT01952080)]), Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, and 156
Change From Baseline in PS Caloric Intake at 12 Weeks Interval up to Week 156 of Retrospective Observation Period
Change from baseline in PS caloric intake at 12 weeks interval up to Week 156 of retrospective observation period was reported. Here, kilo-calories per kilogram per day was abbreviated as (kcal/kg/day).
Time frame: Baseline (Baseline visit in the core study [TED-C13-003 (NCT01952080)]), Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, and 156
Percent Change From Baseline in PS Caloric Intake at 12 Weeks Interval up to Week 156 of Retrospective Observation Period
Percent change from baseline in PS caloric intake at 12 weeks interval up to Week 156 of retrospective observation period was reported.
Time frame: Baseline (Baseline visit in the core study [TED-C13-003 (NCT01952080)]), Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, and 156
Change From Baseline in Number of Hours Per Day of PS Usage at 12 Weeks Interval up to Week 156 of Retrospective Observation Period
Data for this outcome measure was not analyzed and collected because changes from baseline for prescribed hours per day were not collected at baseline in the core study.
Time frame: Baseline (Baseline visit in the core study [TED-C13-003 (NCT01952080)]) up to Week 156
Percent Change From Baseline in Number of Hours Per Day of PS Usage at 12 Weeks Interval up to Week 156 of Retrospective Observation Period
Data for this outcome measure was not analyzed and collected because changes from baseline for prescribed hours per day were not collected at baseline in the core study. Hence, percent change was not assessed in this study.
Time frame: Baseline (Baseline visit in the core study [TED-C13-003 (NCT01952080)]) up to Week 156
Change From Baseline in Number of Days Per Week of PS Usage at 12 Weeks Interval up to Week 156 of Retrospective Observation Period
Change from baseline in number of days per Week of PS usage at 12 weeks interval up to Week 156 in retrospective observation period was reported.
Time frame: Baseline (Baseline visit in the core study [TED-C13-003 (NCT01952080)]), Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, and 156
Percent Change From Baseline in Number of Days Per Week of PS Usage at 12 Weeks Interval up to Week 156 of Retrospective Observation Period
Percent change from baseline in number of days per Week of PS usage at 12 weeks interval up to Week 156 in retrospective observation period was reported.
Time frame: Baseline (Baseline visit in the core study [TED-C13-003 (NCT01952080)]), Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, and 156
Number of Participants Who Achieved At Least 20, 50 and 75% Reduction in PS Volume at EOT of Each Cycle During the End of Teduglutide Treatment Period of Prospective Study Period
Number of participants who achieved at least 20, 50 and 75% reduction in PS volume at EOT of each cycle during the end of teduglutide treatment period in prospective study period was reported.
Time frame: At EOT of each Cycles 1 to 6 (up to Week 140) (length of each Cycle 1 to 5 = 24 weeks, length of Cycle 6 = 20 weeks)
Change From Baseline in PS Volume at EOT of Each Cycle During the End of Teduglutide Treatment Period of Prospective Study Period
Change from baseline in PS volume at EOT of each cycle during the end of teduglutide treatment period in prospective study period was reported.
Time frame: Baseline (from the beginning of the prospective study period), EOT of each Cycles 1 to 6 (up to Week 136) (length of each Cycle 1 to 5 = 24 weeks, length of Cycle 6 = 16 weeks)
Percent Change From Baseline in PS Volume at EOT of Each Cycle During the End of Teduglutide Treatment Period of Prospective Study Period
Percent change from baseline in PS volume at EOT of each cycle during the end of teduglutide treatment period in prospective study period.
Time frame: Baseline (from the beginning of the prospective study period), EOT of each Cycles 1 to 6 (up to Week 136) (length of each Cycle 1 to 5 = 24 weeks, length of Cycle 6 = 16 weeks)
Change From Baseline in PS Caloric Intake at EOT of Each Cycle During the End of Teduglutide Treatment Period of Prospective Study Period
Change from baseline in PS caloric intake at EOT of each cycle during the end of teduglutide treatment period in prospective study period was reported.
Time frame: Baseline (from the beginning of the prospective study period), EOT of each Cycles 1 to 6 (up to Week 136) (length of each Cycle 1 to 5 = 24 weeks, length of Cycle 6 = 16 weeks)
Percent Change From Baseline in PS Caloric Intake at EOT of Each Cycle During the End of Teduglutide Treatment Period of Prospective Study Period
Percent change from baseline in PS caloric intake at EOT of each cycle during the end of teduglutide treatment period in prospective study period was reported.
Time frame: Baseline (from the beginning of the prospective study period), EOT of each Cycles 1 to 6 (up to Week 136) (length of each Cycle 1 to 5 = 24 weeks, length of Cycle 6 = 16 weeks)
Number of Participants Who Achieved 100% Reduction in Complete Weaning of PS Volume at EOT of Each Cycle During the End of Teduglutide Treatment Period of Prospective Study Period
Number of participants who achieved at least 100% reduction in complete weaning of PS volume at EOT of each cycle during the end of teduglutide treatment period in prospective study period was reported.
Time frame: At EOT of each Cycles 1 to 6 (up to Week 144) (length of each Cycle 1 to 6 = 24 weeks)
Change From Baseline in Number of Hours Per Day of PS Usage at EOT of Each Cycle During the End of Teduglutide Treatment Period of Prospective Study Period
Change from baseline in number of hours per day of PS usage at EOT of each cycle during the end of teduglutide treatment period in prospective study period was reported.
Time frame: Baseline (from the beginning of the prospective study period), EOT of each Cycles 1 to 6 (up to Week 136) (length of each Cycle 1 to 5 = 24 weeks, length of Cycle 6 = 16 weeks)
Percent Change From Baseline in Number of Hours Per Day of PS Usage at EOT of Each Cycle During the End of Teduglutide Treatment Period of Prospective Study Period
Percent change from baseline in number of hours per day of PS usage at EOT of each cycle during the end of teduglutide treatment period in prospective study period was reported.
Time frame: Baseline (from the beginning of the prospective study period), EOT of each Cycles 1 to 6 (up to Week 136) (length of each Cycle 1 to 5 = 24 weeks, length of Cycle 6 = 16 weeks)
Change From Baseline in Number of Days Per Week of PS Usage at EOT of Each Cycle During the End of Teduglutide Treatment Period of Prospective Study Period
Change from baseline in number of days per week of PS usage at EOT of each cycle during the end of teduglutide treatment period in prospective study period was reported.
Time frame: Baseline (from the beginning of the prospective study period), EOT of each Cycles 1 to 6 (up to Week 136) (length of each Cycle 1 to 5 = 24 weeks, length of Cycle 6 = 16 weeks)
Percent Change From Baseline in Number of Days Per Week of PS Usage at EOT of Each Cycle During the End of Teduglutide Treatment Period of Prospective Study Period
Percent change from baseline in number of days per week of PS usage at EOT of each cycle during the end of teduglutide treatment period in prospective study period was reported.
Time frame: Baseline (from the beginning of the prospective study period), EOT of each Cycles 1 to 6 (up to Week 136) (length of each Cycle 1 to 5 = 24 weeks, length of Cycle 6 = 16 weeks)
Change From Baseline In Pediatric Quality of Life Inventory (PedsQL) Generic Core Scale (GCS) Score at Week 12 and 24 of Each Treatment Cycle During the Teduglutide Treatment Periods of Prospective Study Period
PedsQL GCS was used for quality of life assessment. It encompasses 4 dimensions of functioning (physical, emotional, social, school). Age groups are: Toddler (2-4 years), Young child (5-7 years), Child (8-12 years), and Teens (13-18 years). Depending on the participants age, the questionnaire may be completed by either the participant or the parent/caregiver as appropriate. For the Toddler group, the PedsQL GCS consisted of 21 items, using a 5-point Likert scale (0 to 4); for all other groups, the PedsQL GCS consisted of 23 items, with a 3-point Likert scale (0, 2, 4) for the young child, and a 5-point Likert scale for the child and teens groups. Scores are transformed on a scale from 0 to 100 where 0=100, 1=75, 2=50, 3=25, and 4=0. Higher scores indicate improved quality of life.
Time frame: Baseline (from the beginning of the prospective study period), Week 12 and 24 of Cycles 1 to 6
Change From Baseline In Pediatric Quality of Life Inventory (PedsQL) Generic Core Scale (GCS) Score at End of Last NTT Period During the NTT Periods in Prospective Study Period
PedsQL GCS was used for quality of life assessment. It encompasses 4 dimensions of functioning (physical, emotional, social, school). Age groups are: Toddler (2-4 years), Young child (5-7 years), Child (8-12 years), and Teens (13-18 years). Depending on the participants age, the questionnaire may be completed by either the participant or the parent/caregiver as appropriate. For the Toddler group, the PedsQL GCS consisted of 21 items, using a 5-point Likert scale (0 to 4); for all other groups, the PedsQL GCS consisted of 23 items, with a 3-point Likert scale (0, 2, 4) for the young child, and a 5-point Likert scale for the child and teens groups. Scores are transformed on a scale from 0 to 100 where 0=100, 1=75, 2=50, 3=25, and 4=0. Higher scores indicate improved quality of life.
Time frame: Baseline (from the beginning of the prospective study period), End of Last NTT period (up to Week 120)
Change From Baseline In Pediatric Quality of Life Inventory (PedsQL) Family Impact Module Total Score at Week 12 and 24 of Each Treatment Cycle During the Teduglutide Treatment Periods of Prospective Study Period
PedsQL Family Impact Module was composed of 36 items comprising Physical Functioning (6 items), Emotional Functioning (5 items), Social Functioning (4 items), Cognitive Functioning (5 items), Communication (3 items), Worry (5 items), Daily Activities (3 items) and Family Relationships (5 items). Total score was calculated as the sum of all the items over the number of items answered on all the scales. Scores are transformed on a scale from 0 to 100 were 0=100, 1=75, 2=50, 3=25, and 4=0. Higher scores indicate improved quality of life.
Time frame: Baseline (from the beginning of the prospective study period), Week 12 and 24 of Cycles 1 to 6
Change From Baseline In Pediatric Quality of Life Inventory (PedsQL) Family Impact Module Total Score at End of Last NTT Period During the NTT Periods in Prospective Study Period
PedsQL Family Impact Module was composed of 36 items comprising Physical Functioning (6 items), Emotional Functioning (5 items), Social Functioning (4 items), Cognitive Functioning (5 items), Communication (3 items), Worry (5 items), Daily Activities (3 items) and Family Relationships (5 items). Total score was calculated as the sum of all the items over the number of items answered on all the scales. Scores are transformed on a scale from 0 to 100 were 0=100, 1=75, 2=50, 3=25, and 4=0. Higher scores indicate improved quality of life.
Time frame: Baseline (from the beginning of to the end the prospective study period), End of Last NTT period (up to Week 120)
Change From Baseline In Pediatric Quality of Life Inventory (PedsQL) Gastrointestinal Symptoms Module at Week 12 and 24 of Each Treatment Cycle During the Teduglutide Treatment Periods of Prospective Study Period
PedsQL GI symptoms module was composed of 58 items, comprised of 10 different symptom scales that assess gastrointestinal symptom-related quality of life: food and drink limits, trouble swallowing, heartburn and reflux, nausea and vomiting, gas and bloating, constipation, blood in poop, and diarrhea. Only the scales of food and drink limits (6 items) and diarrhea (7 items) was used in this study. Subscale score was calculated as the sum of the items over the number of items answered in the scale. Scores are transformed on a scale from 0 to 100 were 0=100, 1=75, 2=50, 3=25, and 4=0. Higher scores indicate improved quality of life.
Time frame: Baseline (from the beginning of the prospective study period), Week 12 and 24 of Cycles 1 to 6
Change From Baseline In Pediatric Quality of Life Inventory (PedsQL) Gastrointestinal Symptoms Module at End of Last NTT Period During the NTT Periods in Prospective Study Period
PedsQL GI symptoms module was composed of 58 items, comprised of 10 different symptom scales that assess gastrointestinal symptom-related quality of life: food and drink limits, trouble swallowing, heartburn and reflux, nausea and vomiting, gas and bloating, constipation, blood in poop, and diarrhea. Only the scales of food and drink limits (6 items) and diarrhea (7 items) was used in this study. Subscale score was calculated as the sum of the items over the number of items answered in the scale. Scores are transformed on a scale from 0 to 100 were 0=100, 1=75, 2=50, 3=25, and 4=0. Higher scores indicate improved quality of life.
Time frame: Baseline (from the beginning of the prospective study period), End of Last NTT period (up to Week 120)
Participants who completed TED-C13-003 (NCT01952080) were enrolled in this study which was conducted at 11 sites in the United States and United Kingdom between 09 December 2016 (first participant first visit) and 14 July 2020 (last participant last visit).
| Milestone | Retrospective TED/NTT Group | Retrospective TED/TED Group | Prospective TED/NTT Group | Prospective TED/TED Group |
|---|---|---|---|---|
| Started | 24 | 5 | 0 | 0 |
| Completed | 20 | 4 | 0 | 0 |
| Not completed | 4 | 1 | 0 | 0 |
| Withdrew: Inform consent not signed by participant | 4 | 1 | 0 | 0 |
| Milestone | Retrospective TED/NTT Group | Retrospective TED/TED Group | Prospective TED/NTT Group | Prospective TED/TED Group |
|---|---|---|---|---|
| Started | 0 | 0 | 5 | 19 |
| Completed | 0 | 0 | 4 | 15 |
| Not completed | 0 | 0 | 1 | 4 |
| Withdrew: Discontinued the study early but didn't complete an et visit. | 0 | 0 | 1 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 4 |
An AE was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. A SAE was any untoward medical occurrence (whether considered to be related to investigational product or not) that at any dose: results in death, was life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, was a congenital abnormality/birth defect, was an important medical event. Number of participants with AEs, related AEs, serious adverse events (SAEs) and related SAEs of retrospective observation period were reported.
| Participants | Retrospective TED/NTT Group | Retrospective TED/TED Group |
|---|---|---|
| Participants with AEs | 23 | 4 |
| Participants with Related AEs | 23 | 4 |
| Participants with SAEs | 23 | 4 |
| Participants with Related SAE | 0 | 0 |
Height was measured using age Z-score. Z-score was calculated as (observed value - median value of the reference population) / standard deviation value of reference population. Centers for Disease Control and Prevention (age greater than or equal to \[\>=\] 2 years old) and World Health Organization (age less than \[\<\] 2 years old) Z-score calculation charts are used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in height for age Z-score up to Week 168 of retrospective observation period was reported. Data for this outcome was not planned to be collected and analyzed in retrospective TED/TED group.
| Z-score | Retrospective TED/NTT Group |
|---|---|
| Change From Baseline in Height for Age Z-score up to Week 168 of Retrospective Observation Period | 0.128 ± 0.0505 |
Body weight was measured using age Z-score. Z-score was calculated as (observed value - median value of the reference population) / standard deviation value of reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts are used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in body weight for age Z-score up to Week 168 was reported. Data for this outcome was not planned to be collected and analyzed in retrospective TED/TED group.
| Z-score | Retrospective TED/NTT Group |
|---|---|
| Change From Baseline in Body Weight for Age Z-score up to Week 168 of Retrospective Observation Period | -0.181 ± 0.0601 |
BMI Z-score was calculated by using the retrospective height and weight data. Z-score was calculated as (observed value - median value of the reference population) / standard deviation value of reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts are used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in height for age Z-score up to Week 168 of retrospective observation period was reported. Data for this outcome was not planned to be collected and analyzed in retrospective TED/TED group.
| Z-score | Retrospective TED/NTT Group |
|---|---|
| Change From Baseline in Body Mass Index (BMI) for Age Z-score up to Week 168 of Retrospective Observation Period | -0.283 ± 0.0646 |
TEAEs are defined as AEs that started or worsened on or after the first dose of teduglutide treatment in the core study. A SAE was any untoward medical occurrence (whether considered to be related to investigational product or not) that at any dose: results in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, was a congenital abnormality/birth defect, was an important medical event. AESI was an TEAE or TESAE of scientific and medical concern specific to the sponsor's product or program and for which ongoing monitoring and immediate notification by the investigator to the sponsor. Number of participants With TEAEs, treatment -emergent serious adverse events (TESAEs) and adverse events of special interest (AESI) of Prospective study period were reported.
| Participants | Prospective TED/NTT Group | Prospective TED/TED Group |
|---|---|---|
| Participants with TEAEs | 4 | 19 |
| Participants with TESAEs | 3 | 17 |
| Participants with AESI | 0 | 0 |
Height was measured using age Z-score. Z-score was calculated as (observed value - median value of the reference population) / standard deviation value of reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts are used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in height for age Z-score up to Cycle 6 Week 12 during the end of teduglutide treatment period in prospective study period was reported.
| Z-score | Prospective TED/TED Group |
|---|---|
| Change From Baseline in Height for Age Z-score up to Cycle 6 Week 12 During the End of Teduglutide Treatment Period of Prospective Study Period | 0.05 ± 1.068 |
Body weight was measured using age Z-score. Z-score was calculated as (observed value - median value of the reference population) / standard deviation value of reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts are used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in body weight for age Z-score up to Cycle 6 Week 24 during the end of teduglutide treatment period of prospective study period was reported.
| Z-score | Prospective TED/TED Group |
|---|---|
| Change From Baseline in Body Weight for Age Z-score up to Cycle 6 Week 24 During the End of Teduglutide Treatment Period of Prospective Study Period | -0.66 ± NA |
BMI Z-score was calculated by using the height and weight data. Z-score was calculated as (observed value - median value of the reference population) / standard deviation value of reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts are used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in BMI for age Z-score up to Cycle 6 Week 12 during the end of teduglutide treatment period of prospective study period was reported.
| Z-score | Prospective TED/TED Group |
|---|---|
| Change From Baseline in BMI for Age Z-score up to Cycle 6 Week 12 During the End of Teduglutide Treatment Period of Prospective Study Period | -0.68 ± 0.349 |
Average total urine output was calculated based on the daily data recorded in participants diaries over a 48-hour period of nutritional stability prior to each scheduled visit. Average total 48-Hour urine output up to Cycle 6 Week 12 during the end of teduglutide treatment period of prospective study period was reported. Here, mL/kg/day is abbreviated as milliliter per kilogram per day.
| mL/kg/day | Prospective TED/TED Group |
|---|---|
| Average Total 48-Hour Urine Output up to Cycle 6 Week 12 During the End of Teduglutide Treatment Period of Prospective Study Period | 14.38 ± 12.712 |
Average total urine output was calculated based on the daily data recorded in participants diaries over a 48-hour period of nutritional stability prior to each scheduled visit. Average total 48-Hour urine output up to Week 108 during the end of NTT period in prospective study period was reported.
| mL/kg/day | Prospective TED/NTT Group |
|---|---|
| Average Total 48-Hour Urine Output up to Week 108 During the End of Non-Teduglutide Treatment (NTT) Period of Prospective Study Period | 22.86 ± 9.956 |
Average number of stools per day was calculated based on the daily data recorded in participants diaries over a 48-hour period of nutritional stability prior to each scheduled visit. Average number of stools per day up to cycle 6 week 24 during the end of teduglutide treatment period in prospective study period was reported.
| Stools per day | Prospective TED/TED Group |
|---|---|
| Average Number of Stools Per Day up to Cycle 6 Week 24 During the End of Teduglutide Treatment Period of Prospective Study Period | 5.50 ± NA |
Average number of stools per day was calculated based on the daily data recorded in participants diaries over a 48-hour period of nutritional stability prior to each scheduled visit. Average number of stools per day up to Week 120 during the end of NTT period in prospective study period was reported.
| Stools per day | Prospective TED/NTT Group |
|---|---|
| Average Number of Stools Per Day up to Week 120 During the End of NTT Period of Prospective Study Period | 3.75 ± 3.182 |
Number of participants with positive specific antibodies to teduglutide were used to summarize the presence of antibodies.
| Participants | Prospective TED/TED Group |
|---|---|
| Number of Participants With Positive Specific Antibodies at EOS During the End of Teduglutide Treatment Period of Prospective Study Period | 1 |
Number of participants achieved at least 20% reduction in PS volume at 12 weeks interval up to Week 156 in retrospective observation period was reported.
| Participants | Retrospective TED/NTT Group | Retrospective TED/TED Group |
|---|---|---|
| At Week 12 | 12 | 2 |
| At Week 24 | 9 | 2 |
| At Week 36 | 9 | 4 |
| At Week 48 | 9 | 4 |
| At Week 60 | 9 | 4 |
| At Week 72 | 6 | 2 |
| At Week 84 | 7 | 2 |
| At Week 96 | 10 | 5 |
| At Week 108 | 9 | 5 |
| At Week 120 | 10 | 4 |
| At Week 132 | 7 | 4 |
| At Week 144 | 3 | 1 |
| At Week 156 | 0 | 1 |
Change from baseline in PS volume at 12 weeks interval up to Week 156 in retrospective observation period was reported.
| mL/kg/day | Retrospective TED/NTT Group | Retrospective TED/TED Group |
|---|---|---|
| Change at Week 12 | -14.45 ± 17.770 | -12.84 ± 17.694 |
| Change at Week 24 | -9.27 ± 21.642 | -13.49 ± 14.530 |
| Change at Week 36 | -10.65 ± 20.877 | -17.91 ± 17.069 |
| Change at Week 48 | -12.24 ± 29.646 | -26.12 ± 8.044 |
| Change at Week 60 | -13.85 ± 30.219 | -21.35 ± 12.285 |
| Change at Week 72 | -13.65 ± 30.577 | -11.41 ± 22.030 |
| Change at Week 84 | -8.74 ± 36.078 | -15.65 ± 19.603 |
| Change at Week 96 | -12.87 ± 37.996 | -27.34 ± 16.531 |
| Change at Week 108 | -10.35 ± 29.370 | -31.83 ± 14.872 |
| Change at Week 120 | -12.21 ± 27.480 | -30.48 ± 19.043 |
| Change at Week 132 | -19.20 ± 26.171 | -37.70 ± 12.296 |
| Change at Week 144 | -16.79 ± 29.620 | -34.32 ± NA |
| Change at Week 156 | -7.46 ± 1.931 | -34.43 ± NA |
Percent change from baseline in PS volume at 12 weeks interval up to Week 156 of retrospective observation period was reported.
| Percent change | Retrospective TED/NTT Group | Retrospective TED/TED Group |
|---|---|---|
| Percent change at Week 12 | -24.50 ± 27.853 | -24.88 ± 35.649 |
| Percent change at Week 24 | -10.72 ± 33.081 | -32.10 ± 31.645 |
| Percent change at Week 36 | -13.21 ± 34.172 | -43.09 ± 42.753 |
| Percent change at Week 48 | -14.04 ± 39.390 | -65.18 ± 31.650 |
| Percent change at Week 60 | -16.15 ± 39.491 | -53.61 ± 37.141 |
| Percent change at Week 72 | -14.19 ± 40.558 | -14.11 ± 58.452 |
| Percent change at Week 84 | -8.67 ± 47.108 | -30.25 ± 39.598 |
| Percent change at Week 96 | -12.04 ± 51.631 | -61.19 ± 29.335 |
| Percent change at Week 108 | -10.62 ± 48.820 | -73.43 ± 29.298 |
| Percent change at Week 120 | -12.89 ± 49.366 | -69.61 ± 39.194 |
| Percent change at Week 132 | -20.24 ± 47.431 | -85.92 ± 17.457 |
| Percent change at Week 144 | -7.70 ± 44.170 | -65.20 ± NA |
| Percent change at Week 156 | -17.21 ± 3.164 | -65.42 ± NA |
Change from baseline in PS caloric intake at 12 weeks interval up to Week 156 of retrospective observation period was reported. Here, kilo-calories per kilogram per day was abbreviated as (kcal/kg/day).
| kcal/kg/day | Retrospective TED/NTT Group | Retrospective TED/TED Group |
|---|---|---|
| Change at Week 12 | -10.15 ± 13.026 | -2.64 ± 18.739 |
| Change at Week 24 | -3.96 ± 16.970 | -7.25 ± 11.916 |
| Change at Week 36 | -8.38 ± 17.148 | -6.42 ± 24.547 |
| Change at Week 48 | -9.84 ± 22.144 | -18.11 ± 7.896 |
| Change at Week 60 | -10.55 ± 23.136 | -10.53 ± 18.538 |
| Change at Week 72 | -12.64 ± 23.642 | -0.05 ± 23.552 |
| Change at Week 84 | -9.70 ± 24.860 | -5.24 ± 23.064 |
| Change at Week 96 | -10.08 ± 23.998 | -15.09 ± 18.604 |
| Change at Week 108 | -7.20 ± 22.875 | -19.05 ± 18.229 |
| Change at Week 120 | -7.98 ± 21.425 | -17.18 ± 23.169 |
| Change at Week 132 | -12.93 ± 18.744 | -27.59 ± 5.114 |
| Change at Week 144 | -11.97 ± 17.977 | -25.53 ± NA |
| Change at Week 156 | -6.55 ± 4.708 | -25.67 ± NA |
Percent change from baseline in PS caloric intake at 12 weeks interval up to Week 156 of retrospective observation period was reported.
| Percent change | Retrospective TED/NTT Group | Retrospective TED/TED Group |
|---|---|---|
| Percent change at Week 12 | -24.91 ± 29.001 | 7.64 ± 82.061 |
| Percent change at Week 24 | -10.12 ± 42.431 | -21.29 ± 37.759 |
| Percent change at Week 36 | -18.29 ± 41.070 | -3.38 ± 118.167 |
| Percent change at Week 48 | -21.03 ± 43.924 | -59.31 ± 38.042 |
| Percent change at Week 60 | -20.63 ± 44.903 | -25.65 ± 83.470 |
| Percent change at Week 72 | -25.48 ± 45.035 | 23.26 ± 99.380 |
| Percent change at Week 84 | -20.42 ± 45.287 | 4.41 ± 102.162 |
| Percent change at Week 96 | -21.12 ± 46.005 | -36.49 ± 72.357 |
| Percent change at Week 108 | -16.41 ± 46.034 | -50.24 ± 70.513 |
| Percent change at Week 120 | -18.79 ± 45.774 | -38.58 ± 97.750 |
| Percent change at Week 132 | -29.37 ± 40.170 | -82.01 ± 21.165 |
| Percent change at Week 144 | -25.25 ± 33.618 | -60.36 ± NA |
| Percent change at Week 156 | -15.66 ± 7.700 | -60.69 ± NA |
Data for this outcome measure was not analyzed and collected because changes from baseline for prescribed hours per day were not collected at baseline in the core study.
No measurements were reported for this outcome.
Data for this outcome measure was not analyzed and collected because changes from baseline for prescribed hours per day were not collected at baseline in the core study. Hence, percent change was not assessed in this study.
No measurements were reported for this outcome.
Change from baseline in number of days per Week of PS usage at 12 weeks interval up to Week 156 in retrospective observation period was reported.
| Days per week | Retrospective TED/NTT Group | Retrospective TED/TED Group |
|---|---|---|
| Change at Week 12 | -0.38 ± 1.469 | -1.20 ± 2.683 |
| Change at Week 24 | -0.29 ± 1.429 | -1.00 ± 2.000 |
| Change at Week 36 | -0.43 ± 1.562 | -2.60 ± 2.793 |
| Change at Week 48 | -0.61 ± 2.017 | -4.50 ± 2.082 |
| Change at Week 60 | -0.61 ± 2.017 | -3.00 ± 3.536 |
| Change at Week 72 | -0.64 ± 2.060 | -1.40 ± 2.966 |
| Change at Week 84 | -0.64 ± 2.060 | -1.40 ± 2.966 |
| Change at Week 96 | -1.17 ± 2.665 | -2.00 ± 3.536 |
| Change at Week 108 | -0.88 ± 2.365 | -3.80 ± 3.701 |
| Change at Week 120 | -0.95 ± 2.459 | -3.80 ± 3.701 |
| Change at Week 132 | -1.00 ± 2.542 | -5.25 ± 2.062 |
| Change at Week 144 | 0.00 ± 0.000 | -3.00 ± NA |
| Change at Week 156 | 0.00 ± 0.000 | -3.00 ± NA |
Percent change from baseline in number of days per Week of PS usage at 12 weeks interval up to Week 156 in retrospective observation period was reported.
| Percent change | Retrospective TED/NTT Group | Retrospective TED/TED Group |
|---|---|---|
| Percent change at Week 12 | -6.25 ± 22.421 | -14.86 ± 41.913 |
| Percent change at Week 24 | -4.17 ± 20.412 | -14.29 ± 28.571 |
| Percent change at Week 36 | -6.21 ± 22.309 | -34.86 ± 44.648 |
| Percent change at Week 48 | -8.70 ± 28.810 | -64.29 ± 29.738 |
| Percent change at Week 60 | -8.70 ± 28.810 | -40.57 ± 54.638 |
| Percent change at Week 72 | -9.09 ± 29.424 | -17.71 ± 45.821 |
| Percent change at Week 84 | -9.09 ± 29.424 | -17.71 ± 45.821 |
| Percent change at Week 96 | -16.67 ± 38.069 | -26.29 ± 53.886 |
| Percent change at Week 108 | -12.50 ± 33.783 | -52.00 ± 57.407 |
| Percent change at Week 120 | -13.64 ± 35.125 | -52.00 ± 57.407 |
| Percent change at Week 132 | -14.29 ± 36.314 | -75.00 ± 29.451 |
| Percent change at Week 144 | 0.00 ± 0.000 | -42.86 ± NA |
| Percent change at Week 156 | 0.00 ± 0.000 | -42.86 ± NA |
Number of participants who achieved at least 20, 50 and 75% reduction in PS volume at EOT of each cycle during the end of teduglutide treatment period in prospective study period was reported.
| Participants | Prospective TED/TED Group |
|---|---|
| Cycle 1: EOT at >= 20% | 13 |
| Cycle 2: EOT at >= 20% | 12 |
| Cycle 3: EOT at >= 20% | 10 |
| Cycle 4: EOT at >= 20% | 9 |
| Cycle 5: EOT at >= 20% | 7 |
| Cycle 6: EOT at >= 20% | 5 |
| Cycle 1: EOT at >= 50% | 5 |
| Cycle 2: EOT at >= 50% | 10 |
| Cycle 3: EOT at >= 50% | 9 |
| Cycle 4: EOT at >= 50% | 9 |
| Cycle 5: EOT at >= 50% | 5 |
| Cycle 6: EOT at >= 50% | 4 |
| Cycle 1: EOT at >= 75% | 2 |
| Cycle 2: EOT at >= 75% | 4 |
| Cycle 3: EOT at >= 75% | 6 |
| Cycle 4: EOT at >= 75% | 5 |
| Cycle 5: EOT at >= 75% | 4 |
| Cycle 6: EOT at >= 75% | 3 |
Change from baseline in PS volume at EOT of each cycle during the end of teduglutide treatment period in prospective study period was reported.
| mL/kg/day | Prospective TED/TED Group |
|---|---|
| Change at Cycle 1: EOT | -25.18 ± 19.915 |
| Change at Cycle 2: EOT | -28.59 ± 29.856 |
| Change at Cycle 3: EOT | -40.05 ± 29.711 |
| Change at Cycle 4: EOT | -40.10 ± 30.359 |
| Change at Cycle 5: EOT | -40.49 ± 24.259 |
| Change at Cycle 6: EOT | -47.57 ± 26.243 |
Percent change from baseline in PS volume at EOT of each cycle during the end of teduglutide treatment period in prospective study period.
| Percent change | Prospective TED/TED Group |
|---|---|
| Percent change: Cycle 1: EOT | -38.02 ± 28.611 |
| Percent change: Cycle 2: EOT | -45.58 ± 48.150 |
| Percent change: Cycle 3: EOT | -62.16 ± 41.805 |
| Percent change: Cycle 4: EOT | -62.92 ± 38.466 |
| Percent change: Cycle 5: EOT | -73.49 ± 34.593 |
| Percent change: Cycle 6: EOT | -78.75 ± 33.949 |
Change from baseline in PS caloric intake at EOT of each cycle during the end of teduglutide treatment period in prospective study period was reported.
| kcal/kg/day | Prospective TED/TED Group |
|---|---|
| Change at Cycle 1: EOT | -17.66 ± 17.649 |
| Change at Cycle 2: EOT | -19.95 ± 23.402 |
| Change at Cycle 3: EOT | -27.66 ± 19.668 |
| Change at Cycle 4: EOT | -24.05 ± 22.746 |
| Change at Cycle 5: EOT | -26.98 ± 27.465 |
| Change at Cycle 6: EOT | -27.53 ± 32.486 |
Percent change from baseline in PS caloric intake at EOT of each cycle during the end of teduglutide treatment period in prospective study period was reported.
| Percent change | Prospective TED/TED Group |
|---|---|
| Percent change at Cycle 1: EOT | -33.50 ± 40.439 |
| Percent change at Cycle 2: EOT | -42.06 ± 44.077 |
| Percent change at Cycle 3: EOT | -62.47 ± 37.677 |
| Percent change at Cycle 4: EOT | -49.51 ± 54.041 |
| Percent change at Cycle 5: EOT | -54.08 ± 64.002 |
| Percent change at Cycle 6: EOT | -59.00 ± 57.267 |
Number of participants who achieved at least 100% reduction in complete weaning of PS volume at EOT of each cycle during the end of teduglutide treatment period in prospective study period was reported.
| Participants | Prospective TED/TED Group |
|---|---|
| Cycle 1: EOT | 1 |
| Cycle 2: EOT | 3 |
| Cycle 3: EOT | 6 |
| Cycle 4: EOT | 5 |
| Cycle 5: EOT | 4 |
| Cycle 6: EOT | 3 |
Change from baseline in number of hours per day of PS usage at EOT of each cycle during the end of teduglutide treatment period in prospective study period was reported.
| Hours per day | Prospective TED/TED Group |
|---|---|
| Change at Cycle 1: EOT | -3.40 ± 3.752 |
| Change at Cycle 2: EOT | -4.80 ± 5.360 |
| Change at Cycle 3: EOT | -6.69 ± 4.247 |
| Change at Cycle 4: EOT | -6.48 ± 4.881 |
| Change at Cycle 5: EOT | -6.71 ± 6.175 |
| Change at Cycle 6: EOT | -8.08 ± 6.075 |
Percent change from baseline in number of hours per day of PS usage at EOT of each cycle during the end of teduglutide treatment period in prospective study period was reported.
| Percent change | Prospective TED/TED Group |
|---|---|
| Percent change at Cycle 1: EOT | -26.32 ± 29.732 |
| Percent change at Cycle 2: EOT | -40.47 ± 40.476 |
| Percent change at Cycle 3: EOT | -57.61 ± 36.973 |
| Percent change at Cycle 4: EOT | -55.87 ± 42.693 |
| Percent change at Cycle 5: EOT | -58.85 ± 52.717 |
| Percent change at Cycle 6: EOT | -66.39 ± 46.042 |
Change from baseline in number of days per week of PS usage at EOT of each cycle during the end of teduglutide treatment period in prospective study period was reported.
| Days per week | Prospective TED/TED Group |
|---|---|
| Change at Cycle 1: EOT | -0.60 ± 1.892 |
| Change at Cycle 2: EOT | -1.93 ± 2.840 |
| Change at Cycle 3: EOT | -3.03 ± 3.257 |
| Change at Cycle 4: EOT | -2.99 ± 3.610 |
| Change at Cycle 5: EOT | -3.83 ± 3.969 |
| Change at Cycle 6: EOT | -4.37 ± 3.618 |
Percent change from baseline in number of days per week of PS usage at EOT of each cycle during the end of teduglutide treatment period in prospective study period was reported.
| Percent change | Prospective TED/TED Group |
|---|---|
| Percent change at Cycle 1: EOT | -9.01 ± 27.472 |
| Percent change at Cycle 2: EOT | -29.24 ± 40.525 |
| Percent change at Cycle 3: EOT | -44.51 ± 47.929 |
| Percent change at Cycle 4: EOT | -42.38 ± 51.929 |
| Percent change at Cycle 5: EOT | -54.29 ± 57.404 |
| Percent change at Cycle 6: EOT | -62.86 ± 51.110 |
PedsQL GCS was used for quality of life assessment. It encompasses 4 dimensions of functioning (physical, emotional, social, school). Age groups are: Toddler (2-4 years), Young child (5-7 years), Child (8-12 years), and Teens (13-18 years). Depending on the participants age, the questionnaire may be completed by either the participant or the parent/caregiver as appropriate. For the Toddler group, the PedsQL GCS consisted of 21 items, using a 5-point Likert scale (0 to 4); for all other groups, the PedsQL GCS consisted of 23 items, with a 3-point Likert scale (0, 2, 4) for the young child, and a 5-point Likert scale for the child and teens groups. Scores are transformed on a scale from 0 to 100 where 0=100, 1=75, 2=50, 3=25, and 4=0. Higher scores indicate improved quality of life.
| Score on a scale | Prospective TED/TED Group |
|---|---|
| Physical Functioning: Change at Cycle 1 Week 12 | -0.39 ± 24.326 |
| Physical Functioning: Change at Cycle 1 Week 24 | -0.83 ± 10.726 |
| Physical Functioning: Change at Cycle 2 Week 12 | 2.34 ± 15.717 |
| Physical Functioning: Change at Cycle 2 Week 24 | 2.40 ± 16.296 |
| Physical Functioning: Change at Cycle 3 Week 12 | -0.57 ± 16.167 |
| Physical Functioning: Change at Cycle 3 Week 24 | -1.74 ± 25.963 |
| Physical Functioning: Change at Cycle 4 Week 12 | -1.74 ± 22.378 |
| Physical Functioning: Change at Cycle 4 Week 24 | 1.79 ± 19.998 |
| Physical Functioning: Change at Cycle 5 Week 12 | -7.50 ± 19.961 |
| Physical Functioning: Change at Cycle 5 Week 24 | -2.34 ± 14.292 |
| Physical Functioning: Change at Cycle 6 Week 12 | -6.25 ± 22.244 |
| Physical Functioning: Change at Cycle 6 Week 24 | 3.13 ± NA |
| Emotional Functioning: Change at Cycle 1 Week 12 | 4.17 ± 18.843 |
| Emotional Functioning: Change at Cycle 1 Week 24 | -4.67 ± 24.511 |
| Emotional Functioning: Change at Cycle 2 Week 12 | -3.33 ± 28.591 |
| Emotional Functioning: Change at Cycle 2 Week 24 | -0.38 ± 21.454 |
| Emotional Functioning: Change at Cycle 3 Week 12 | 7.05 ± 29.661 |
| Emotional Functioning: Change at Cycle 3 Week 24 | -8.33 ± 36.120 |
| Emotional Functioning: Change at Cycle 4 Week 12 | 2.78 ± 33.481 |
| Emotional Functioning: Change at Cycle 4 Week 24 | -0.71 ± 35.786 |
| Emotional Functioning: Change at Cycle 5 Week 12 | -11.00 ± 40.566 |
| Emotional Functioning: Cycle 5 Week 24 | -17.50 ± 37.804 |
| Emotional Functioning: Change at Cycle 6 Week 12 | -5.63 ± 56.065 |
| Emotional Functioning: Change at Cycle 6 Week 24 | 17.50 ± NA |
| Social Functioning: Change at Cycle 1 Week 12 | -15.00 ± NA |
| Social Functioning: Change at Cycle 1 Week 24 | -10.00 ± NA |
| Social Functioning: Change at Cycle 2 Week 12 | -5.00 ± NA |
| Social Functioning: Change at Cycle 2 Week 24 | 0.00 ± NA |
| Social Functioning: Change at Cycle 3 Week 12 | 10.00 ± NA |
| Social Functioning: Change at Cycle 3 Week 24 | 0.00 ± NA |
| Social Functioning: Change at Cycle 4 Week 12 | 10.00 ± NA |
| Social Functioning: Change at Cycle 4 Week 24 | 10.00 ± NA |
| Social Functioning: Change at Cycle 5 Week 12 | 10.00 ± NA |
| Social Functioning: Change at Cycle 5 Week 24 | 10.00 ± NA |
| Social Functioning: Change at Cycle 6 Week 12 | 10.00 ± NA |
| School Functioning: Change at Cycle 1 Week 12 | 5.67 ± 19.445 |
| School Functioning: Change at Cycle 1 Week 24 | 2.00 ± 20.160 |
| School Functioning: Change at Cycle 2 Week 12 | -5.00 ± 24.027 |
| School Functioning: Change at Cycle 2 Week 24 | 8.75 ± 16.394 |
| School Functioning: Change at Cycle 3 Week 12 | 3.64 ± 23.355 |
| School Functioning: Change at Cycle 3 Week 24 | -3.33 ± 22.500 |
| School Functioning: Change at Cycle 4 Week 12 | 0.00 ± 15.000 |
| School Functioning: Change at Cycle 4 Week 24 | 13.57 ± 8.018 |
| School Functioning: Change at Cycle 5 Week 12 | 15.00 ± 11.180 |
| School Functioning: Change at Cycle 5 Week 24 | 18.75 ± 8.539 |
| School Functioning: Change at Cycle 6 Week 12 | 13.75 ± 4.787 |
| School Functioning: Change at Cycle 6 Week 24 | 20.00 ± NA |
PedsQL GCS was used for quality of life assessment. It encompasses 4 dimensions of functioning (physical, emotional, social, school). Age groups are: Toddler (2-4 years), Young child (5-7 years), Child (8-12 years), and Teens (13-18 years). Depending on the participants age, the questionnaire may be completed by either the participant or the parent/caregiver as appropriate. For the Toddler group, the PedsQL GCS consisted of 21 items, using a 5-point Likert scale (0 to 4); for all other groups, the PedsQL GCS consisted of 23 items, with a 3-point Likert scale (0, 2, 4) for the young child, and a 5-point Likert scale for the child and teens groups. Scores are transformed on a scale from 0 to 100 where 0=100, 1=75, 2=50, 3=25, and 4=0. Higher scores indicate improved quality of life.
No measurements were reported for this outcome.
PedsQL Family Impact Module was composed of 36 items comprising Physical Functioning (6 items), Emotional Functioning (5 items), Social Functioning (4 items), Cognitive Functioning (5 items), Communication (3 items), Worry (5 items), Daily Activities (3 items) and Family Relationships (5 items). Total score was calculated as the sum of all the items over the number of items answered on all the scales. Scores are transformed on a scale from 0 to 100 were 0=100, 1=75, 2=50, 3=25, and 4=0. Higher scores indicate improved quality of life.
| Score on a scale | Prospective TED/TED Group |
|---|---|
| Change at Cycle 1 Week 12 | 1.39 ± 15.742 |
| Change at Cycle 1 Week 24 | 1.56 ± 13.372 |
| Change at Cycle 2 Week 12 | 0.10 ± 13.622 |
| Change at Cycle 2 Week 24 | 1.90 ± 11.664 |
| Change at Cycle 3 Week 12 | 2.72 ± 15.051 |
| Change at Cycle 3 Week 24 | 3.90 ± 16.018 |
| Change at Cycle 4 Week 12 | 2.14 ± 20.762 |
| Change at Cycle 4 Week 24 | 4.66 ± 23.546 |
| Change at Cycle 5 Week 12 | 0.11 ± 14.105 |
| Change at Cycle 5 Week 24 | 2.23 ± 16.099 |
| Change at Cycle 6 Week 12 | 5.13 ± 18.084 |
| Change at Cycle 6 Week 24 | -17.86 ± NA |
PedsQL Family Impact Module was composed of 36 items comprising Physical Functioning (6 items), Emotional Functioning (5 items), Social Functioning (4 items), Cognitive Functioning (5 items), Communication (3 items), Worry (5 items), Daily Activities (3 items) and Family Relationships (5 items). Total score was calculated as the sum of all the items over the number of items answered on all the scales. Scores are transformed on a scale from 0 to 100 were 0=100, 1=75, 2=50, 3=25, and 4=0. Higher scores indicate improved quality of life.
No measurements were reported for this outcome.
PedsQL GI symptoms module was composed of 58 items, comprised of 10 different symptom scales that assess gastrointestinal symptom-related quality of life: food and drink limits, trouble swallowing, heartburn and reflux, nausea and vomiting, gas and bloating, constipation, blood in poop, and diarrhea. Only the scales of food and drink limits (6 items) and diarrhea (7 items) was used in this study. Subscale score was calculated as the sum of the items over the number of items answered in the scale. Scores are transformed on a scale from 0 to 100 were 0=100, 1=75, 2=50, 3=25, and 4=0. Higher scores indicate improved quality of life.
| Score on a scale | Prospective TED/TED Group |
|---|---|
| Food and Drink Limits: Change at Cycle 1 Week 12 | -2.08 ± 30.460 |
| Food and Drink Limits: Change at Cycle 1 Week 24 | -7.06 ± 27.524 |
| Food and Drink Limits: Change at Cycle 2 Week 12 | -0.83 ± 29.723 |
| Food and Drink Limits: Change at Cycle 2 Week 24 | 9.31 ± 26.292 |
| Food and Drink Limits: Change at Cycle 3 Week 12 | 1.19 ± 35.784 |
| Food and Drink Limits: Change at Cycle 3 Week 24 | -0.08 ± 29.511 |
| Food and Drink Limits: Change at Cycle 4 Week 12 | -4.63 ± 33.750 |
| Food and Drink Limits: Change at Cycle 4 Week 24 | 1.04 ± 35.895 |
| Food and Drink Limits: Change at Cycle 5 Week 12 | 1.19 ± 21.343 |
| Food and Drink Limits: Change at Cycle 5 Week 24 | -17.36 ± 44.986 |
| Food and Drink Limits: Change at Cycle 6 Week 12 | -1.39 ± 30.142 |
| Food and Drink Limits: Change at Cycle 6 Week 24 | -45.83 ± NA |
| Diarrhea: Change at Cycle 1 Week 12 | 7.79 ± 23.137 |
| Diarrhea: Change at Cycle 1 Week 24 | 9.33 ± 23.279 |
| Diarrhea: Change at Cycle 2 Week 12 | 5.48 ± 15.144 |
| Diarrhea: Change at Cycle 2 Week 24 | 6.72 ± 19.880 |
| Diarrhea: Change at Cycle 3 Week 12 | 13.27 ± 22.124 |
| Diarrhea: Change at Cycle 3 Week 24 | 5.19 ± 21.569 |
| Diarrhea: Change at Cycle 4 Week 12 | 9.13 ± 18.653 |
| Diarrhea: Change at Cycle 4 Week 24 | 12.95 ± 26.448 |
| Diarrhea: Change at Cycle 5 Week 12 | 10.71 ± 23.237 |
| Diarrhea: Change at Cycle 5 Week 24 | 8.33 ± 30.612 |
| Diarrhea: Change at Cycle 6 Week 12 | 5.95 ± 22.961 |
| Diarrhea: Change at Cycle 6 Week 24 | -7.14 ± NA |
PedsQL GI symptoms module was composed of 58 items, comprised of 10 different symptom scales that assess gastrointestinal symptom-related quality of life: food and drink limits, trouble swallowing, heartburn and reflux, nausea and vomiting, gas and bloating, constipation, blood in poop, and diarrhea. Only the scales of food and drink limits (6 items) and diarrhea (7 items) was used in this study. Subscale score was calculated as the sum of the items over the number of items answered in the scale. Scores are transformed on a scale from 0 to 100 were 0=100, 1=75, 2=50, 3=25, and 4=0. Higher scores indicate improved quality of life.
No measurements were reported for this outcome.
Collected over From start of screening up to end of the study (up to 168 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Retrospective TED/NTT Group | 0/24 (0%) | 23/24 (95.8%) | 1/24 (4.2%) |
| Retrospective TED/TED Group | 0/5 (0%) | 4/5 (80%) | 1/5 (20%) |
| Prospective TED/NTT Group | 0/5 (0%) | 3/5 (60%) | 4/5 (80%) |
| Prospective TED/TED Group | 0/19 (0%) | 17/19 (89.5%) | 18/19 (94.7%) |
| Event | Retrospective TED/NTT Group | Retrospective TED/TED Group | Prospective TED/NTT Group | Prospective TED/TED Group |
|---|---|---|---|---|
| Device related infectionInfections and infestations | 17/24 | 2/5 | 1/5 | 9/19 |
| PyrexiaGeneral disorders | 14/24 | 3/5 | 0/5 | 7/19 |
| Device breakageProduct Issues | 6/24 | 1/5 | 0/5 | 0/19 |
| InfluenzaInfections and infestations | 5/24 | 0/5 | 0/5 | 4/19 |
| Device malfunctionProduct Issues | 5/24 | 1/5 | 0/5 | 0/19 |
| Abdominal adhesionsGastrointestinal disorders | 0/24 | 0/5 | 1/5 | 0/19 |
| IleusGastrointestinal disorders | 1/24 | 1/5 | 0/5 | 2/19 |
| Intestinal obstructionGastrointestinal disorders | 0/24 | 0/5 | 1/5 | 0/19 |
| CellulitisInfections and infestations | 0/24 | 0/5 | 1/5 | 1/19 |
| CystitisInfections and infestations | 0/24 | 0/5 | 1/5 | 0/19 |
| Event | Retrospective TED/NTT Group | Retrospective TED/TED Group | Prospective TED/NTT Group | Prospective TED/TED Group |
|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 0/24 | 0/5 | 3/5 | 7/19 |
| VomitingGastrointestinal disorders | 0/24 | 0/5 | 2/5 | 10/19 |
| Abdominal painGastrointestinal disorders | 0/24 | 1/5 | 2/5 | 7/19 |
| Viral upper respiratory tract infectionInfections and infestations | 0/24 | 0/5 | 2/5 | 0/19 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/24 | 0/5 | 0/5 | 6/19 |
| DiarrhoeaGastrointestinal disorders | 0/24 | 0/5 | 0/5 | 5/19 |
| C-reactive protein increasedInvestigations | 0/24 | 0/5 | 0/5 | 5/19 |
| HeadacheNervous system disorders | 0/24 | 0/5 | 1/5 | 5/19 |
| RashSkin and subcutaneous tissue disorders | 0/24 | 0/5 | 1/5 | 4/19 |
| AnaemiaBlood and lymphatic system disorders | 0/24 | 0/5 | 1/5 | 3/19 |
Safety population included all enrolled participants who provided informed consent for the prospective portion and met all the inclusion criteria.
| Age, Continuous(Years) | Retrospective TED/NTT Group | Retrospective TED/TED Group | Total |
|---|---|---|---|
| Mean | 4.0 ± 2.88 | 8.2 ± 5.50 | 4.7 ± 3.71 |
| Sex: Female, Male(Participants) | Retrospective TED/NTT Group | Retrospective TED/TED Group | Total |
|---|---|---|---|
| Female | 9 | 0 | 9 |
| Male | 15 | 5 | 20 |
| Race/Ethnicity, Customized(Participants) | Retrospective TED/NTT Group | Retrospective TED/TED Group | Total |
|---|---|---|---|
| Ethnicity — Hispanic or Latino | 9 | 1 | 10 |
| Ethnicity — Not Hispanic or Latino | 15 | 3 | 18 |
| Ethnicity — Not allowed based on local regulations | 0 | 1 | 1 |
| Race/Ethnicity, Customized(Participants) | Retrospective TED/NTT Group | Retrospective TED/TED Group | Total |
|---|---|---|---|
| Race — White | 20 | 3 | 23 |
| Race — Black or African American | 2 | 1 | 3 |
| Race — Asian | 0 | 1 | 1 |
| Race — Other | 2 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — De-identified individual participant data from this particular study will not be shared as the data are subject to contractual (or consent) provisions that prohibit transfer to third parties.
Ran from Dec 2016 to primary completion in Jul 2020, 43 months.
Results were first posted in Jun 2021, 11 months after primary completion.
Of 26 industry-sponsored phase 3 interventional studies under Short Bowel Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 43 months is above that.
Counting every sponsor, half of 27 studies reached it within 37 months; a quarter within 24 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Teduglutide